Booming GPL-1 Sales at Lilly
Mounjaro Sales Q2-26 $9.94B Zepbound SALES Q2-26 $4.93B All other SALES Q2-26 $6.98B Eli Lilly & Co. filed its Q2 earnings this morning . That gives us an excellent excuse to crack open the Calcbench databases and dine on Lilly’s disclosures about its blockbuster weight-loss drugs Zepbound and Mounjaro. As we’ve noted before in these pages, pharmaceutical firms disclose the sales of their individual blockbuster drugs. So we opened our Segments, Rollforwards & Breakouts page , called up Lilly’s ($LLY) quarterly revenues for Zepbound and Mounjaro, and then compared the sales of those two drugs against all Lilly’s other products. The result is Figure 1, below. As you can see, Lilly’s two GLP-1 weight loss drugs went from 26.5 percent of total sales at the start of 2024 ($2.32 billion against $8.77 billion) to two-thirds of total sales today ($14.9 billion of $23 billion). Figure 2, below, takes all that information and reframes it in dollar amounts. Again, the tale is...